DGAP-News

MOLOGEN to present two posters at ESMO IO 2015 (news with additional features)

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN to present two posters at ESMO IO 2015 (news with additional
features)

18.11.2015 / 09:20

---------------------------------------------------------------------

Berlin, 18 November 2015 - The biotechnology company MOLOGEN AG (ISIN
DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present
two posters on the immunotherapy MGN1703 at the ESMO Symposium on
Immuno-Oncology 2015 (ESMO IO) in Lausanne
(20 - 21 November 2015). The first poster focuses on the randomized IMPULSE
trial in patients with small cell lung cancer (SCLC). In a second poster
data on the safety, pharmacokinetics and pharmacodynamics from a phase I
study with MGN1703 in healthy volunteers will be shown.

Abstract details:
1. Title: "Immunomodulatory switch maintenance therapy to improve overall
survival in small cell lung cancer (SCLC): The randomized IMPULSE study"
2. Title: "Safety, pharmacokinetics and pharmacodynamics from a clinical
trial with healthy volunteers using the immunotherapeutic TLR9 agonist
MGN1703"

Presentation: 20 November 2015, 6 p.m. (both posters)

For more information on the ESMO IO 2015 please visit:
http://www.esmo.org/Conferences/Immuno-Oncology-2015.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and
strong activation of the immune system. Due to this mechanism of action,
MGN1703 has the potential to be applied to various indications. MGN1703 is
currently being developed for first-line maintenance treatment of
colorectal cancer (pivotal study) and small cell lung cancer (randomized
controlled trial). Furthermore it is also being investigated in a phase I
study in HIV.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical
industry e.V. (VCI)

MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of
MOLOGEN AG.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
[e-mail]

Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.



+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=LYSSPPIKLI
Document title: Press Release

---------------------------------------------------------------------

18.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: [e-mail]
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart


End of News DGAP News Service
---------------------------------------------------------------------
414237 18.11.2015